Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Castillo BV Jr, Kaufman L. Pediatric tumors of the eye and orbit. Pediatr Clin North Am. 2003;50(1):149–172. doi:10.1016/S0031-3955(02)00115-3
   PubMed Web of Science ®Google Scholar
• Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013;60(5):719–727. doi:10.1002/pbc.24468
   PubMed Web of Science ®Google Scholar
• Canadian Retinoblastoma S. National retinoblastoma strategy canadian guidelines for care: strategie therapeutique du retinoblastome guide clinique canadien. Can J Ophthalmol. 2009;44(Suppl 2):S1–S88.
   PubMedGoogle Scholar
• Honavar SG, Singh AD. Management of advanced retinoblastoma. Ophthalmol Clin North Am. 2005;18(1):65–73, viii. doi:10.1016/j.ohc.2004.09.001
   PubMedGoogle Scholar
• Scelfo C, Francis JH, Khetan V, et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol. 2017;10(6):961–967.
   PubMed Web of Science ®Google Scholar
• McDaid C, Hartley S, Bagnall AM, Ritchie G, Light K, Riemsma R. Systematic review of effectiveness of different treatments for childhood retinoblastoma. Health Technol Assess. 2005;9(48):iii, ix–x, 1–145. doi:10.3310/hta9480
   Web of Science ®Google Scholar
• Fabian ID, Reddy A, Sagoo MS.Classification and staging of retinoblastoma. Community Eye Health.2018;31(101):11–13.
   Google Scholar
• Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–2280. doi:10.1016/j.ophtha.2006.06.018
   PubMed Web of Science ®Google Scholar
• Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Heon E. Management and outcome of unilateral retinoblastoma. J AAPOS. 2009;13(6):546–550. doi:10.1016/j.jaapos.2009.09.004
   Web of Science ®Google Scholar
• Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 2002;120(4):460–464. doi:10.1001/archopht.120.4.460
   Google Scholar
• Ghassemi F, Chams H, Sabour S, et al. Characteristics of germline and non-germline retinoblastomas. J Ophthalmic Vis Res. 2014;9(2):188–194.
   Google Scholar
• Yousef YA, AlNawaiseh T, AlJabari R, Muhsen S, Al-Nawaiseh I. Retinoblastoma awareness among first contact physicians in Jordan. Ophthalmic Genet. 2019;40(3):191–195. doi:10.1080/13816810.2019.1605387
   PubMed Web of Science ®Google Scholar
• Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol. 2002;120(12):1653–1658. doi:10.1001/archopht.120.12.1653
   Google Scholar
• Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35(4):193–207. doi:10.3109/13816810.2014.973045
   PubMed Web of Science ®Google Scholar
• Munier FL, Soliman S, Moulin AP, Gaillard MC, Balmer A, Beck-Popovic M. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012;96(8):1084–1087. doi:10.1136/bjophthalmol-2011-301016
   PubMed Web of Science ®Google Scholar
• Rubin CM, Robison LL, Cameron JD, et al. Intraocular retinoblastoma group V: an analysis of prognostic factors. J Clin Oncol. 1985;3(5):680–685. doi:10.1200/JCO.1985.3.5.680
   Web of Science ®Google Scholar
• Chen Q, Zhang B, Dong Y, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta- analysis. BMC Cancer. 2018;18(1):486. doi:10.1186/s12885-018-4406-6
   PubMed Web of Science ®Google Scholar
• Yousef YA, Hajja Y, Nawaiseh I, et al. A histopathologic analysis of 50 eyes primarily enucleated for retinoblastoma in a tertiary cancer center in Jordan. Turk Patoloji Derg. 2014;30(3):171–177.
   Google Scholar
• Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011;29(7):845–851. doi:10.1200/JCO.2010.32.5332
   Web of Science ®Google Scholar
• Meel R, Radhakrishnan V, Bakhshi S. Current therapy and recent advances in the management of retinoblastoma. Indian J Med Paediatr Oncol. 2012;33(2):80–88. doi:10.4103/0971-5851.99731
   PubMedGoogle Scholar
• Houston SK, Murray TG, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. Int Ophthalmol Clin. 2011;51(1):77–91. doi:10.1097/IIO.0b013e3182010f29
   PubMedGoogle Scholar
• Cohen VM, Kingston J, Hungerford JL. The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol. 2009;93(7):887–890. doi:10.1136/bjo.2008.142679
   PubMed Web of Science ®Google Scholar
• Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol. 2004;138(3):329–337. doi:10.1016/j.ajo.2004.04.032
   PubMed Web of Science ®Google Scholar
• Sultan I, Hajja Y, Nawaiseh I, et al. Chemoreduction of progressive intraocular retinoblastoma by systemic topotecan. Ophthalmic Genet. 2016;37(2):209–213. doi:10.3109/13816810.2015.1039138
   PubMed Web of Science ®Google Scholar
• Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet. 2004;25(1):37–43. doi:10.1076/opge.25.1.37.28996
   Google Scholar
• Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy. Indian J Ophthalmol. 2015;63(2):103–109. doi:10.4103/0301-4738.154369
   PubMed Web of Science ®Google Scholar
• Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502. doi:10.1136/bjophthalmol-2011-300498
   PubMed Web of Science ®Google Scholar
• Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399–1406. doi:10.1001/archophthalmol.2011.150
   PubMedGoogle Scholar
• Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004;24(6):849–862. doi:10.1097/00006982-200412000-00003
   PubMed Web of Science ®Google Scholar
• Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97(10):1231–1236. doi:10.1136/bjophthalmol-2013-303188
   PubMed Web of Science ®Google Scholar
• Yousef YA, Soliman SE, Astudillo PPP, et al. Intra-arterial chemotherapy for retinoblastoma: a systematic review. JAMA Ophthalmol. 2016;134(5):584–591. doi:10.1001/jamaophthalmol.2016.0244
   PubMed Web of Science ®Google Scholar
• Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268–1271. doi:10.1001/archophthalmol.2012.1983
   PubMedGoogle Scholar
• Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol. 2005;123(11):1525–1530. doi:10.1001/archopht.123.11.1525
   Google Scholar
• Yousef YA, Al-Nawaiseh I, Mehyar M, et al. How telemedicine and centralized care changed the natural history of retinoblastoma in a developing country: analysis of 478 patients. Ophthalmology. 2020;S0161-6420(20)30689–8. doi:10.1016/j.ophtha.2020.07.026
   Web of Science ®Google Scholar
• Mallipatna AC, Gallie BL, Chévez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, editors. AJCC Cancer Staging Manual. 8th. New York: Springer; 2017:819–831.
   Google Scholar